China
Africa
Explore chapters and articles related to this topic
Infectious Disease
Published in John S. Axford, Chris A. O'Callaghan, Medicine for Finals and Beyond, 2023
Susanna J. Dunachie, Hanif Esmail, Ruth Corrigan, Maria Dudareva
The mainstay of management is supportive care with oxygen if required to maintain saturations above 92%, and monitoring of end-organ function.Clinical trials continue to reveal beneficial adjuvant therapies for COVID-19, including dexamethasone, antivirals (remdesevir, molnupiravir and Paxlovid), IL-6 blockade (toclizumab) and monoclonal antibodies (Ronapreve and Sotrovimab). Local up-to-date management guidelines should be consulted.
Antibodies to watch in 2022
Published in mAbs, 2022
Hélène Kaplon, Alicia Chenoweth, Silvia Crescioli, Janice M. Reichert
On March 27, 2021, the FDA issued an EUA for sotrovimab (VIR-7831; GSK4182136) for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progression to severe COVID-19, including hospitalization or death.16 Sotrovimab is a human anti-SARS-CoV-2 IgG1ҡ antibody derived from the B cell of a COVID-19 survivor. An application for the use of sotrovimab for COVID-19 is under rolling review in the EU. EMA’s CHMP issued a positive scientific opinion on emergency use of sotrovimab for COVID-19 in May 2021. Sotrovimab has also been authorized for emergency use in other areas, including Japan. VIR and GSK plan to submit a Biologics License Application (BLA) to the FDA in the first half of 2022.
Use of Sotrovimab in a cohort of pregnant women with a high risk of COVID 19 progression: a single-center experience
Published in Pathogens and Global Health, 2023
Luisa Frallonardo, Antonella Vimercati, Roberta Novara, Cherola Lepera, Ilaria Ferrante, Giulia Chiarello, Rossana Cicinelli, Michele Mongelli, Gaetano Brindicci, Francesco Vladimiro Segala, Carmen Rita Santoro, Davide Fiore Bavaro, Nicola Laforgia, Ettore Cicinelli, Annalisa Saracino, Francesco Di Gennaro
Our cohort describes the use of the MAb Sotrovimab in 13 pregnant women with moderate COVID-19 disease to evaluate its effectiveness and safety. From our data, no adverse events were reported and no one had progression of diseases related to COVID. Sotrovimab, formerly known as VIR-7831, is a human monoclonal antibody that neutralizes SARS-CoV-2 and multiple other sarbecoviruses, including SARS-CoV-1, the virus responsible for the first pandemic of the twenty-first century. [13,14]
Monoclonal antibody therapies in the management of SARS-CoV-2 infection
Published in Expert Opinion on Investigational Drugs, 2022
Enrique Miguez-Rey, Dasom Choi, Seungmin Kim, Sangwook Yoon, Oana Săndulescu
Sotrovimab (VIR-7831) is an investigational dual-action SARS-CoV-2 NAb with the potential to both block viral entry into healthy cells and clear infected cells [74]. VIR-7831 was derived from a parent antibody isolated from a recovered patient who had been infected with SARS-CoV in 2003.